The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease

Respir Med. 2019 Apr:150:45-50. doi: 10.1016/j.rmed.2019.02.007. Epub 2019 Feb 12.

Abstract

Purpose: We aimed to investigate the natural history of non-cavitary nodular bronchiectatic (NC-NB) Mycobacterium avium complex (MAC) lung disease (LD).

Methods: Among all patients diagnosed with NC-NB MAC LD between March 2000 and December 2013, 551 patients who were followed until December 2017 were enrolled at a tertiary referral center in South Korea. Patients were subdivided into progressive and stationary groups, depending on whether treatment was initiated within 3 years after diagnosis. We investigated the proportion of patients not receiving anti-MAC treatment within 3 years after the diagnosis. The rate for spontaneous sputum conversion in the untreated group was also calculated.

Results: The mean age of 551 patients was 61.1 years. During the median 5.8 years of follow-up, 323 (58.6%) patients received treatment within 3 years (progressive group), whereas the remaining 228 (41.4%) patients did not (stationary group). Multivariate analysis revealed that age ≤ 60 years, a positive sputum smear, the presence of systemic symptoms, body mass index >18.5 kg/m2, and the involvement of ≥ 4 lobes were predictors of receiving treatment. Additionally, during the median of 5.0 years follow-up, spontaneous sputum conversion occurred in 52.2% of patients who did not receive treatment.

Conclusions: Among patients diagnosed with NC-NB MAC LD, approximately 40% did not receive antibiotic treatment within 3 years of diagnosis. Moreover, about 50% of untreated patients experienced spontaneous sputum conversion.

Keywords: Clinical course; Conversion; MAC; Treatment.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anti-Bacterial Agents / standards
  • Anti-Bacterial Agents / therapeutic use
  • Bronchiectasis / complications*
  • Bronchiectasis / pathology
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Diseases / microbiology*
  • Male
  • Middle Aged
  • Mycobacterium avium Complex / isolation & purification*
  • Mycobacterium avium-intracellulare Infection / diagnosis*
  • Mycobacterium avium-intracellulare Infection / drug therapy
  • Mycobacterium avium-intracellulare Infection / epidemiology
  • Mycobacterium avium-intracellulare Infection / microbiology*
  • Prevalence
  • Remission, Spontaneous
  • Republic of Korea / epidemiology
  • Retrospective Studies
  • Sputum / drug effects
  • Sputum / microbiology

Substances

  • Anti-Bacterial Agents